|
NCT04568863
|
Efficacy of Intravenous Melatonin on Mortality in Adult Patients Admitted to the Intensive Care Unit With COVID-19 |
Completed |
Phase 2 |
Jun/20/2020 |
Nov/30/2020 |
- Alternative id - PHM-2020-001
- Interventions - Drug: Melatonin intravenous|Drug: Placebo intravenous
- Study type - Interventional
- Study results - No Results Available
- Locations - Hospital Universitario La Paz, Madrid, Spain
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 18
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Mortality
|
|
NCT04530539
|
The Effect of Melatonin and Vitamin C on COVID-19 |
Active, not recruiting |
Not Applicable |
Oct/05/2020 |
Jun/30/2022 |
- Alternative id - 2020-68
- Interventions - Dietary Supplement: Vitamin C|Dietary Supplement: melatonin|Dietary Supplement: Placebo|Other: Symptom Survey
- Study type - Interventional
- Study results - No Results Available
- Locations - Lancaster General Health, Lancaster, Pennsylvania, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care
- Enrollment - 122
- Age - 50 Years and older (Adult, Older Adult)
- Outcome measures - Symptom Severity|Symptom progression
|
|
NCT04353128
|
Efficacy of Melatonin in the Prophylaxis of Coronavirus Disease 2019 (COVID-19) Among Healthcare Workers. |
Completed |
Phase 2|Phase 3 |
Apr/20/2020 |
Dec/01/2020 |
- Alternative id - MeCOVID
- Interventions - Drug: Melatonin 2mg|Drug: Placebo oral tablet
- Study type - Interventional
- Study results - No Results Available
- Locations - Hospital Universitario La Paz, Madrid, Spain
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
- Enrollment - 450
- Age - 18 Years to 65 Years (Adult, Older Adult)
- Outcome measures - SARS-CoV 2 infection rate
|
|
NCT04409522
|
Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients |
Recruiting |
Not Applicable |
May/12/2020 |
Sep/25/2020 |
- Alternative id - IR.BMSU.REC.1399.039
- Interventions - Drug: Melatonin|Drug: The usual treatment
- Study type - Interventional
- Study results - No Results Available
- Locations - Mohammad Sadegh Bagheri Baghdasht, Tehran, Iran, Islamic Republic of
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 55
- Age - 16 Years to 100 Years (Child, Adult, Older Adult)
- Outcome measures - Melatonin|Inflammatory cytokines|C-reactive protein (CRP)|Cough|Oxygen saturation of the blood|ESR|Radiological Treatment Response|Inflammatory route
|
|
NCT04474483
|
Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19 |
Recruiting |
Phase 2 |
Nov/06/2020 |
Dec/31/2022 |
- Alternative id - UBMELCOVID19
- Interventions - Drug: Melatonin|Other: Placebo (Methylcellulose) capsule
- Study type - Interventional
- Study results - No Results Available
- Locations - University at Buffalo, Buffalo, New York, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 30
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Cumulative Incidence of Treatment-Emergent Adverse Events|Hospitalization|COVID-19 related symptoms|Rate of resolution of COVID-19 related symptoms|Mortality
|
|
NCT04784754
|
Dose-Ranging Study to Assess the Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19 |
Recruiting |
Phase 2 |
Apr/01/2021 |
Dec/31/2022 |
- Alternative id - UBMELCOVID19-P|UL1TR001412
- Interventions - Drug: Melatonin|Drug: Placebo
- Study type - Interventional
- Study results - No Results Available
- Locations - University at Buffalo, Buffalo, New York, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 50
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Cumulative Incidence of Treatment-Emergent Adverse Events|Incidence of COVID-19 related hospitalization|COVID-19 related symptoms|Rate of resolution of COVID-19 related symptoms|Mortality
|
|
NCT04570254
|
Antioxidants as Adjuvant Therapy to Standard Therapy in Patients With COVID-19 |
Completed |
Not Applicable |
Aug/19/2020 |
Dec/01/2020 |
- Alternative id - 09-CEI-011-20160627
- Interventions - Drug: Vitamin C|Drug: Vitamin E|Drug: Melatonin|Drug: N-acetyl cysteine|Drug: Pentoxifylline
- Study type - Interventional
- Study results - No Results Available
- Locations - Unidad Temporal COVID-19 en Centro Citibanamex, Mexico City, Mexico
- Study designs - Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 110
- Age - Child, Adult, Older Adult
- Outcome measures - Death from any cause|Percentage of patients who required orotracheal intubation|Assisted mechanical ventilation|Stay in an intensive care unit|Measure lipoperoxidation in basal and post-therapy samples|Evaluation of the total antioxidant capacity|Oxidative and antioxidant stress|Effect of antioxidant therapy at the level on organ failure secondary to SARS-COV2
|
|
NCT04531748
|
Selective Estrogen Modulation and Melatonin in Early COVID-19 |
Withdrawn |
Phase 2 |
Dec/01/2021 |
Sep/01/2022 |
- Alternative id - 20-842
- Interventions - Drug: Toremifene|Drug: Melatonin|Other: Placebo
- Study type - Interventional
- Study results - No Results Available
- Locations -
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 0
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Peak increase in COVID-19 Sign and Symptom score|Nadir Oxygen Saturation|Peak Heart Rate|Time to COVID-19 Sign and Symptom score resolution|Time to WHO 7-point ordinal scale score of 3 or higher
|
|
NCT04470297
|
Melatonin Agonist on Hospitalized Patients With Confirmed or Suspected COVID-19 |
Not yet recruiting |
Phase 2 |
Sep/01/2020 |
Mar/01/2021 |
- Alternative id - MELCOV2020
- Interventions - Drug: Ramelteon 8mg
- Study type - Interventional
- Study results - No Results Available
- Locations -
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
- Enrollment - 100
- Age - 18 Years to 80 Years (Adult, Older Adult)
- Outcome measures - Time to resolution of symptoms [National Early Warning Score 2 (NEWS2) of 0]|Clinical worsening to critical COVID-19 illness|Duration of supplemental oxygen therapy|Duration of mechanical ventilation (if applicable)|Duration of hospitalisation|Proportion of participants with virologic clearance in nasopharyngeal swab RT-PCR|C-reactive protein (CRP) level's reduction|Incidence of New Onset Lymphopenia|Direct bilirubin level's reduction|Side Effects
|
